Ipilimumab Biosimilar (Prestige BioPharma)

伊匹木单抗生物类似药 (Prestige BioPharma)

Report date: 2024/10/10 10:04:55

Base Information

Drug NameIpilimumab Biosimilar (Prestige BioPharma)
Drug Alias NameYervoy® BiosimilarPBP1701PBP-1701
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrestige BioPharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A